Product
Dimethyl fumarate
7 clinical trials
10 indications
Indication
Multiple SclerosisIndication
Relapsing-RemittingIndication
Intracerebral hemorrhageIndication
StrokeIndication
Intracranial AneurysmIndication
AneurysmIndication
BrainIndication
Vascular inflammationIndication
Cutaneous T-Cell LymphomaIndication
SARSClinical trial
A Multicenter, Postmarketing Study of Dimethyl Fumarate (Tecfidera; BG00012) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaStatus: Active (not recruiting), Estimated PCD: 2025-04-16
Clinical trial
A Retrospective Analysis in Real World on Lymphocyte Reconstitution After Lymphopenia in Patients Treated by Tecfidera and Description of Management Strategies in FranceStatus: Completed, Estimated PCD: 2021-06-15
Clinical trial
Dimethyl Fumarate for the Treatment of Intracerebral HemorrhageStatus: Withdrawn, Estimated PCD: 2021-12-31
Clinical trial
Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic StrokeStatus: Terminated, Estimated PCD: 2023-02-08
Clinical trial
Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms: a Double Blind Randomized Controlled TrailStatus: Not yet recruiting, Estimated PCD: 2023-12-31
Clinical trial
Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
Randomised Evaluation of COVID-19 TherapyStatus: Recruiting, Estimated PCD: 2026-06-30